The Future of Pharma: Patient-Centric, Equity-Driven and Innovation-Led

India’s Pharma Sector: Advancing Innovation, Access and Resilience

India’s pharmaceutical sector is entering a phase where generics strength alone will not define competitiveness. Precision medicine and genomics, rising demand for rare disease therapies, artificial intelligence, and the need for resilient supply chains are reshaping the global healthcare landscape. For India, these shifts create an opportunity to strengthen its position as both a global medicines supplier and a pharmaceutical services market capable of developing solutions for diverse patient needs.

Against this backdrop, the 8th CII Pharma & Life Sciences Summit 2026, to be held on 18 September 2026 in New Delhi, will bring together industry leaders, policymakers, clinicians, researchers, technology innovators, patient groups and academia under the theme “Future of Pharma: Patient-Centric, Equity-Driven, and Innovation-Led”.

The Summit builds on the 7th edition’s focus on sustainability, ESG integration and Industry 5.0 imperatives in pharmaceutical manufacturing, and turns attention to the next set of challenges: how innovation can become more accessible, how patients can have a greater role in shaping solutions, and how value chains can remain resilient amid geopolitical and regulatory uncertainty.

From Manufacturing Strength to Biopharma Innovation

India’s next phase of pharmaceutical growth will increasingly depend on its ability to build capabilities in biologics, biosimilars and other noval modalities of life sciences. The Union Budget 2026-27 introduced the INR 10,000 crore, five-year Biopharma SHAKTI scheme to build India’s biologics and biosimilars ecosystem. Alongside this, the INR 5,000 crore Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme is supporting research across new chemical and biological entities, complex generics and biosimilars, precision medicine, AI-enabled medical devices, orphan drugs and antimicrobial resistance.

The Summit’s opening plenary will examine what it will take to convert these policy and investment efforts into sustained innovation leadership, including stronger clinical trial capabilities, the role of contract research, development and manufacturing organisation (CRDMO) players, and the financing needed to move visionary science from discovery to market. It will also consider how India can strengthen its position as a preferred global partner for complex, innovation-led biopharma programmes while keeping pricing, market access and affordability in view.

Building a Technology-Enabled and Resilient Value Chain

Integration of AI is increasingly relevant across the pharmaceutical value chain, from drug discovery and clinical development to pharmacovigilance, regulatory processes and manufacturing. At the same time, digitalisation must be scalable beyond large organisations, particularly for mid-sized and MSME manufacturers.  The Summit will examine AI-led discovery, real-world evidence, predictive compliance, connected manufacturing and digital traceability, alongside the evolving regulatory environment. The discussion will also address a fundamental industry priority: building supply chains that can withstand geopolitical shifts and disruptions while ensuring reliable domestic availability of medicines. India’s dependence on imported APIs and key starting materials remains a critical concern, with China accounting for roughly 73–74% of India’s API and key starting material imports. Fermentation-based APIs, KSMs, and excipients are particularly important areas to strengthen domestic capacity.

Addressing the Access Gap

Innovation has limited value if patients cannot access its benefits. This is particularly evident in rare diseases, where diagnostic challenges and the high cost of therapies can create significant barriers to care. The Summit will therefore examine how financing mechanisms, patient-assistance programmes, patient advocacy, registries, and  biobanks can contribute to more equitable access. It will also explore the role of insurance-based risk pooling, negotiated procurement and tiered pricing in addressing affordability without weakening long-term innovation incentives.

A Patient-Centric Future for Pharma

The future of Indian pharma will require convergence across science, technology, policy, industry and patient needs. Competitiveness will depend not only on what the sector can develop and manufacture, but also on how effectively innovation reaches patients and how resilient the systems supporting it are. Through four plenary sessions covering biopharma innovation, technology and compliance, value-chain resilience, and rare disease access, the 8th CII Pharma & Life Sciences Summit 2026 will create a platform to examine these interconnected priorities and identify actionable pathways for the sector.

The Summit aims to translate these deliberations into recommendations, industry commitments and collaborative frameworks, culminating in a Summit Declaration on patient-centric, equity-driven and innovation-led healthcare. As India looks to strengthen its role in global healthcare, the next frontier is clear: innovation must move beyond scientific achievement to deliver solutions that are accessible, scalable and resilient.